Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more
Ultragenyx Pharmaceutical Inc. (0LIF) - Net Assets
Latest net assets as of : $- USD
Based on the latest financial reports, Ultragenyx Pharmaceutical Inc. (0LIF) has net assets worth $- USD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Ultragenyx Pharmaceutical Inc. - Net Assets Trend (None–None)
This chart illustrates how Ultragenyx Pharmaceutical Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ultragenyx Pharmaceutical Inc. (None–None)
The table below shows the annual net assets of Ultragenyx Pharmaceutical Inc. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Ultragenyx Pharmaceutical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Ultragenyx Pharmaceutical Inc. Competitors by Market Cap
The table below lists competitors of Ultragenyx Pharmaceutical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhongman Petro & Natural Gas
SHG:603619
|
$2.06 Billion |
|
BBB Foods Inc.
NYSE:TBBB
|
$2.06 Billion |
|
Nanjing Securities Co Ltd
SHG:601990
|
$2.07 Billion |
|
Central Garden & Pet Company
NASDAQ:CENT
|
$2.07 Billion |
|
Hanwha Chemical Corp Pref
KO:009835
|
$2.06 Billion |
|
Bank of Guiyang Co Ltd
SHG:601997
|
$2.06 Billion |
|
Anhui Zhongding Sealing Parts Co Ltd
SHE:000887
|
$2.06 Billion |
|
Fujian Newland Computer Co Ltd
SHE:000997
|
$2.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ultragenyx Pharmaceutical Inc.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Ultragenyx Pharmaceutical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Ultragenyx Pharmaceutical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Ultragenyx Pharmaceutical Inc.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (0LIF) | $- | N/A | N/A | $2.06 Billion |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |